Suchen
Pharvaris NV
PHVSZur Watchlist hinzufügen
33.950USD
-0.630-1.82%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
2.22BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Pharvaris NV Unternehmen
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Pharvaris NV Informationen
BörsenkürzelPHVS
Name des UnternehmensPharvaris NV
IPO-datumFeb 05, 2021
CEOModig (Berndt B.A.E)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 05
AddresseEmmy Noetherweg 2
StadtLEIDEN
BörseNASDAQ OMX - NASDAQ BASIC
LandNetherlands
Postleitzahl2333 BK
Telefon31712036410
Websitehttps://pharvaris.com/
BörsenkürzelPHVS
IPO-datumFeb 05, 2021
CEOModig (Berndt B.A.E)
Führungskräfte von Pharvaris NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
47.61K
-5.61%
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Pharvaris NV?
Die fünf größten Anteilseigner von Pharvaris NV sind: Mr. Berndt Modig, CPA
Wie viele Institutionen halten Anteile an Pharvaris NV (PHVS)?
Mit Stand vom 2026Q1 halten 165 Institutionen Anteile an Pharvaris NV, mit einem Gesamtmarktwert von etwa 59.26M, was 90.60% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -451327.00 gestiegen.